| Year |
Citation |
Score |
| 2022 |
Vietzen H, Döhler B, Tran TH, Süsal C, Halloran PF, Eskandary F, Herz CT, Mayer KA, Kozakowski N, Wahrmann M, Ely S, Haindl S, Puchhammer-Stöckl E, Böhmig GA. Deletion of the Natural Killer Cell Receptor NKG2C Encoding Gene and Kidney Transplant Outcome. Frontiers in Immunology. 13: 829228. PMID 35401541 DOI: 10.3389/fimmu.2022.829228 |
0.302 |
|
| 2020 |
Callemeyn J, Lerut E, de Loor H, Arijs I, Thaunat O, Koenig A, Meas-Yedid V, Olivo-Marin JC, Halloran P, Chang J, Thorrez L, Kuypers D, Sprangers B, Van Lommel L, Schuit F, et al. Transcriptional Changes in Kidney Allografts with Histology of Antibody-Mediated Rejection without Anti-HLA Donor-Specific Antibodies. Journal of the American Society of Nephrology : Jasn. PMID 32641395 DOI: 10.1681/Asn.2020030306 |
0.362 |
|
| 2020 |
Kumar D, Raynaud M, Chang J, Reeve J, Yakubu I, Kamal L, Levy M, Bhati C, Kimball P, King A, Massey D, Halloran P, Gupta G. Impact of Belatacept Conversion on Renal Function, Histology and Gene Expression in Kidney Transplant Patients With Chronic Active Antibody-mediated Rejection. Transplantation. PMID 32510913 DOI: 10.1097/Tp.0000000000003278 |
0.379 |
|
| 2019 |
Viglietti D, Lefaucheur C, Philippe A, Aubert O, Glotz D, Legendre C, Halloran P, Loupy A, Dragun D. FP761NON-HLA AGONISTIC ANTI-ANGIOTENSIN II TYPE 1 RECEPTOR ANTIBODIES INDUCE A DISTINCTIVE PHENOTYPE OF REJECTION IN KIDNEY TRANSPLANT RECIPIENTS: AN OBSERVATIONAL COHORT STUDY Nephrology Dialysis Transplantation. 34. DOI: 10.1093/Ndt/Gfz106.Fp761 |
0.421 |
|
| 2018 |
Halloran P, Chang J, Famulski KS. In Kidney Allografts Inflammation in Scarred Areas is not a Reflection of Chronic Active T Cell-Mediated Rejection Transplantation. 102: S268-S269. DOI: 10.1097/01.Tp.0000542959.10675.B6 |
0.331 |
|
| 2018 |
Lefaucheur C, Viglietti D, Aubert O, Philippe A, Halloran P, Loupy A, Dragun D. Anti-angiotensin II type 1-receptor antibodies (AT1R-Ab) Induce a Specific Phenotype of Rejection Distinct from HLA antibody-Mediated Rejection Transplantation. 102: S254. DOI: 10.1097/01.Tp.0000542940.34438.Bf |
0.323 |
|
| 2018 |
Parkes M, Reeve J, Kim D, Macdonald P, Aliabadi A, Goekler J, Zuckermann A, Bruneval P, Loupy A, Potena L, Crespo-Leiro M, Cadeiras M, Depasquale E, Deng M, Kobashigawa J, ... Halloran P, et al. Molecular Assessment of Heart Transplant Biopsies: Emergence of the Injury Dimension Transplantation. 102. DOI: 10.1097/01.Tp.0000542635.50135.47 |
0.325 |
|
| 2017 |
Lefaucheur C, Viglietti D, Hidalgo LG, Ratner LE, Bagnasco SM, Batal I, Aubert O, Orandi BJ, Oppenheimer F, Bestard O, Rigotti P, Reisaeter AV, Kamar N, Lebranchu Y, Duong Van Huyen JP, ... ... Halloran PF, et al. Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. Journal of the American Society of Nephrology : Jasn. PMID 29042454 DOI: 10.1681/Asn.2017050589 |
0.306 |
|
| 2017 |
Lefaucheur C, Sis B, Viglietti D, Mangiola M, Aubert O, Glotz D, Legendre C, Loupy A, Halloran P, Zeevi A. OR50 Complement-binding donor-specific anti-HLA antibodies induce a specific histo-molecular kidney allograft rejection phenotype Human Immunology. 78: 46. DOI: 10.1016/J.Humimm.2017.06.056 |
0.405 |
|
| 2017 |
Lefaucheur C, Viglietti D, Mangiola M, Aubert O, Legendre C, Glotz D, Halloran P, Loupy A, Zeevi A. OR12 Complement-binding donor-specific anti-HLA antibodies predict the response to complement-targeting therapy: A multicenter international study Human Immunology. 78: 14. DOI: 10.1016/J.Humimm.2017.06.018 |
0.399 |
|
| 2016 |
Halloran K, Chang J, Ramassar V, Kapasi A, Weinkauf J, Hirji A, Lien D, Reeve J, Halloran P. Microarray Analysis of Transbronchial Biopsies in Lung Transplant Recipients Detects Molecular Changes of T-cell Mediated Inflammation The Journal of Heart and Lung Transplantation. 35: S234-S235. DOI: 10.1016/J.Healun.2016.01.666 |
0.317 |
|
| 2016 |
Racapé M, Loupy A, Reeve J, Venner J, Guillemain R, Hidalgo L, Lefaucheur C, Jouven X, Bruneval P, Duong Van Huyen J, Halloran P. Molecular Correlates of Endothelial mTOR Activation in Heart Transplant Recipients The Journal of Heart and Lung Transplantation. 35: S17-S18. DOI: 10.1016/J.Healun.2016.01.048 |
0.348 |
|
| 2015 |
Halloran P. Sixteen years of the Roche Organ Transplantation Research Foundation. Transplantation. 99: e35-6. PMID 25692414 DOI: 10.1097/Tp.0000000000000679 |
0.319 |
|
| 2014 |
Wang Z, Famulski K, Lee J, Das SK, Wang X, Halloran P, Oudit GY, Kassiri Z. TIMP2 and TIMP3 have divergent roles in early renal tubulointerstitial injury. Kidney International. 85: 82-93. PMID 23760282 DOI: 10.1038/Ki.2013.225 |
0.337 |
|
| 2014 |
Reeve J, Famulski K, Halloran P. Microarray Gene Expression for Predicting Histo-Clinical Variables in Kidney Transplant Biopsies. Transplantation. 98: 890. DOI: 10.1097/00007890-201407151-03040 |
0.358 |
|
| 2014 |
Famulski K, Reeve J, Halloran P. Proper Interpretation of Molecular Changes Associated With Atrophy-Fibrosis Requires Correction For Time Post-Transplant. Transplantation. 98: 468. DOI: 10.1097/00007890-201407151-01557 |
0.341 |
|
| 2014 |
Halloran P, Reeve J, Famulski K. T Cell-Mediated Rejection Becomes Rare in Late Kidney Transplants Despite Persistent Antibody-Mediated Rejection: Emergence of Split Tolerance. Transplantation. 98: 232. DOI: 10.1097/00007890-201407151-00690 |
0.392 |
|
| 2014 |
Blanco P, Husain S, Halloran P, Sis B. Endothelial Activation, Quantified By Electron Microscopy Scoring or Multiplexed Gene Expression, Predicts Accelerated Graft Loss in Patients With Transplant Glomerulopathy. Transplantation. 98: 230. DOI: 10.1097/00007890-201407151-00684 |
0.322 |
|
| 2014 |
Pereira A, Reeve J, Chang J, Venner J, Famulski K, Halloran P. Post-Transplant Glomerulonephritis Has a Molecular Behavior of Antibody Mediated Rejection. Transplantation. 98: 84. DOI: 10.1097/00007890-201407151-00261 |
0.353 |
|
| 2014 |
Loupy A, Beuscart T, Lefaucheur C, Reeve J, Hidalgo L, Chang J, Francois A, Varnous S, Bories M, Guillemain R, Bruneval P, Jouven X, Duong J, Halloran P. The Molecular Phenotype of Antibody-Mediated Rejection in Heart Transplants.: Abstract# 1374 Transplantation. 98: 57. DOI: 10.1097/00007890-201407151-00186 |
0.353 |
|
| 2014 |
Lefaucheur C, Loupy A, Reeve J, Hidalgo L, Famulski K, Duong J, Chang J, Aubert O, Zeevi A, Jouven X, Glotz D, Legendre C, Halloran P. C1q-Binding DSA Induce Distinct Molecular Phenotypes in Kidney Transplant Biopsies. Transplantation. 98: 6. DOI: 10.1097/00007890-201407151-00013 |
0.393 |
|
| 2013 |
Halloran PF. Transplantation: Autoantibodies-epiphenomena or biological clues. Nature Reviews. Nephrology. 9: 705-6. PMID 24145327 DOI: 10.1038/nrneph.2013.221 |
0.304 |
|
| 2010 |
Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation. 90: 68-74. PMID 20463643 DOI: 10.1097/Tp.0B013E3181E065De |
0.37 |
|
| 2010 |
Gourishankar S, Leduc R, Connett J, Cecka JM, Cosio F, Fieberg A, Gaston R, Halloran P, Hunsicker L, Kasiske B, Rush D, Grande J, Mannon R, Matas A. Pathological and clinical characterization of the 'Troubled transplant': Data from the DeKAF study American Journal of Transplantation. 10: 324-330. PMID 20055809 DOI: 10.1111/J.1600-6143.2009.02954.X |
0.364 |
|
| 2010 |
Matas AJ, Leduc R, Rush D, Cecka JM, Connett J, Fieberg A, Halloran P, Hunsicker L, Cosio F, Grande J, Mannon R, Gourishankar S, Gaston R, Kasiske B. Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: Preliminary data from the DeKAF study American Journal of Transplantation. 10: 315-323. PMID 20041864 DOI: 10.1111/J.1600-6143.2009.02943.X |
0.311 |
|
| 2010 |
Sellarés J, Reeve J, Sis B, Mengel M, Hidalgo LG, Halloran P. Attribution: Classifying Causes Of Kidney Allograft Failure: 3147 Transplantation. 90: 934. DOI: 10.1097/00007890-201007272-01833 |
0.323 |
|
| 2010 |
Reeve J, SellarÉs J, Mengel M, Sis B, Hidalgo LG, Famulski KS, Halloran P. Assigning A Probability Of Tcmr To Kidney Transplant Biopsies.: 3081 Transplantation. 90: 10. DOI: 10.1097/00007890-201007272-00020 |
0.396 |
|
| 2009 |
Hidalgo LG, Campbell PM, Sis B, Einecke G, Mengel M, Chang J, Sellares J, Reeve J, Halloran PF. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure American Journal of Transplantation. 9: 2532-2541. PMID 19843031 DOI: 10.1111/j.1600-6143.2009.02800.x |
0.317 |
|
| 2009 |
Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo RR, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P. Calcineurin inhibitor minimization in the symphony study: Observational results 3 years after transplantation American Journal of Transplantation. 9: 1876-1885. PMID 19563339 DOI: 10.1111/J.1600-6143.2009.02726.X |
0.351 |
|
| 2009 |
Gaston RS, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Halloran P, Hunsicker L, Rush D, Matas AJ. Use of cardioprotective medications in kidney transplant recipients American Journal of Transplantation. 9: 1811-1815. PMID 19519808 DOI: 10.1111/J.1600-6143.2009.02696.X |
0.362 |
|
| 2008 |
Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Klempnauer J, Gürkan A, Margreiter R, Hugo C, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P. Cni Sparing With Mycophenolate Mofetil In De Novo Renal Transplantation: 3-Year Results From The Symphony Study: 623 Transplantation. 86: 218-219. DOI: 10.1097/01.Tp.0000332146.48976.B4 |
0.386 |
|
| 2007 |
Mueller TF, Einecke G, Reeve J, Sis B, Mengel M, Jhangri GS, Bunnag S, Cruz J, Wishart D, Meng C, Broderick G, Kaplan B, Halloran PF. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 7: 2712-22. PMID 17941957 DOI: 10.1111/J.1600-6143.2007.02005.X |
0.316 |
|
| 2005 |
Couser WG, Drueke TB, Halloran PF, Kasiske BL, Klahr S, Morris P. A uniform clinical trial registration policy for journals of kidney diseases, dialysis and transplantation. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 5: 643. PMID 15760385 DOI: 10.1097/00007890-200504150-00001 |
0.328 |
|
| 2003 |
Takeuchi O, Sims TN, Takei Y, Ramassar V, Famulski KS, Halloran PF. Differential usage of class II transactivator promoters PI and PIV during inflammation and injury in kidney. Journal of the American Society of Nephrology : Jasn. 14: 2823-32. PMID 14569092 DOI: 10.1097/01.Asn.0000094084.18567.Cc |
0.684 |
|
| 2003 |
Gonwa T, Johnson C, Ahsan N, Alfrey EJ, Halloran P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation. 75: 2048-53. PMID 12829910 DOI: 10.1097/01.Tp.0000069831.76067.22 |
0.384 |
|
| 2002 |
Gourishankar S, Turner P, Halloran P. New developments in immunosuppressive therapy in renal transplantation. Expert Opinion On Biological Therapy. 2: 483-501. PMID 12079485 DOI: 10.1517/14712598.2.5.483 |
0.374 |
|
| 2002 |
Afrouzian M, Ramassar V, Urmson J, Zhu LF, Halloran PF. Transcription factor IRF-1 in kidney transplants mediates resistance to graft necrosis during rejection. Journal of the American Society of Nephrology : Jasn. 13: 1199-209. PMID 11961007 |
0.33 |
|
| 2002 |
Gourishankar S, Melk A, Halloran P. Nonimmune Mechanisms of Injury in Renal Transplantation Transplantation Reviews. 16: 73-86. DOI: 10.1053/Trre.2002.23263 |
0.405 |
|
| 2001 |
Sims TN, Afrouzian M, Urmson J, Zhu LF, Halloran PF. The role of the class II transactivator (CIITA) in MHC class I and II regulation and graft rejection in kidney. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 1: 211-21. PMID 12102254 DOI: 10.1034/J.1600-6143.2001.001003211.X |
0.709 |
|
| 2001 |
Kung L, Batiuk TD, Palomo-Pinon S, Noujaim J, Helms LM, Halloran PF. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 1: 325-33. PMID 12099376 DOI: 10.1034/J.1600-6143.2001.10407.X |
0.625 |
|
| 2001 |
Cole E, Landsberg D, Russell D, Zaltzman J, Kiberd B, Caravaggio C, Vasquez AR, Halloran P. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation. 72: 845-850. PMID 11571448 DOI: 10.1097/00007890-200109150-00018 |
0.358 |
|
| 2001 |
Ahsan N, Johnson C, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation. 72: 245-50. PMID 11477347 DOI: 10.1097/00007890-200107270-00014 |
0.373 |
|
| 2001 |
Busque S, Shoker A, Landsberg D, McAlister V, Halloran P, Shapiro J, Peets J, Schulz M. Canadian multicentre trial of tacrolimus/azathioprine/steroids versus tacrolimus/mycophenolate mofetil/steroids versus neoral/mycophenolate mofetil/steroids in renal transplantation. Transplantation Proceedings. 33: 1266-1267. PMID 11267285 DOI: 10.1016/S0041-1345(00)02471-4 |
0.386 |
|
| 2001 |
Zaltzman J, McAlister V, Russell D, Halloran P, Landsberg D, Busque S, Shoker A, Boucher A, Shapiro J, Tchervenkov J, Peets J. Tacrolimus, MMF, steroid, and ALG immunotherapy for high immunological risk renal transplant recipients. Transplantation Proceedings. 33: 1044-1045. PMID 11267183 DOI: 10.1016/S0041-1345(00)02323-X |
0.408 |
|
| 2001 |
Halloran PF, Afrouzian M, Ramassar V, Urmson J, Zhu LF, Helms LM, Solez K, Kneteman NM. Interferon-gamma acts directly on rejecting renal allografts to prevent graft necrosis. The American Journal of Pathology. 158: 215-26. PMID 11141495 DOI: 10.1016/S0002-9440(10)63960-0 |
0.304 |
|
| 2001 |
Gourishankar S, Halloran P. Long-term immunosuppressive strategy in the new millennium of renal transplantation Current Opinion in Organ Transplantation. 6: 175-182. DOI: 10.1097/00075200-200106000-00013 |
0.37 |
|
| 2001 |
Halloran P. Book Review Pathology and Immunology of Transplantation and Rejection Edited by Sathia Thiru and Herman Waldmann. 583 pp., illustrated. Malden, Mass., Blackwell Science, 2001. $250. 0-632-03676-1 New England Journal of Medicine. 344: 1953-1954. DOI: 10.1056/Nejm200106213442518 |
0.331 |
|
| 2000 |
Kung L, Halloran PF. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation. 70: 327-35. PMID 10933159 DOI: 10.1097/00007890-200007270-00017 |
0.62 |
|
| 2000 |
Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology. 47: 215-45. PMID 10878291 DOI: 10.1016/S0162-3109(00)00190-9 |
0.319 |
|
| 2000 |
Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation. 69: 834-41. PMID 10755536 DOI: 10.1097/00007890-200003150-00028 |
0.36 |
|
| 2000 |
Takei Y, Sims TN, Urmson J, Halloran PF. Central role for interferon-gamma receptor in the regulation of renal MHC expression. Journal of the American Society of Nephrology : Jasn. 11: 250-61. PMID 10665932 |
0.692 |
|
| 2000 |
Kung L, Gourishankar S, Halloran PF. Molecular pharmacology of immunosuppressive agents in relation to their clinical use Current Opinion in Organ Transplantation. 5: 268-275. DOI: 10.1097/00075200-200009000-00018 |
0.604 |
|
| 2000 |
Busque S, Shoker A, Landsberg D, McAlister V, Halloran P, Shapiro J. CANADIAN MULTICENTRE TRIAL OF PROGRAF/AZA VS. PROGRAF/MMF VS. NEORAL/MMF IN RENAL TRANSPLANTATION. Transplantation. 69: S114. DOI: 10.1097/00007890-200004271-00014 |
0.374 |
|
| 2000 |
Gonwa TA, Johnson C, Ahsan N, Halloran P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, et al. TWO YEAR FOLLOWUP OF A RANDOMIZED MULTICENTER KIDNEY TRANSPLANT STUDY COMPARING TACROLIMUS(PG)+AZATHIOPRINE(AZA) VS. CYCLOSPORINE(NEORAL)+MYCOPHENOLATE MOFETIL(MMF) VS. TACROLIMUS+MMF. Transplantation. 69: S113. DOI: 10.1097/00007890-200004271-00011 |
0.388 |
|
| 1999 |
Sims TN, Halloran PF. MHC class II regulation in vivo in the mouse kidney. Microbes and Infection / Institut Pasteur. 1: 903-12. PMID 10614008 DOI: 10.1016/S1286-4579(99)00227-0 |
0.695 |
|
| 1999 |
Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 68: 1356-61. PMID 10573076 DOI: 10.1097/00007890-199911150-00023 |
0.636 |
|
| 1999 |
Cole E, Landsberg D, Russell D, Zaltzman J, Kiberd B, Halloran P. RENAL TRANSPLANTATION WITHOUT STEROIDS - A MULTICENTRE CANADIAN PILOT STUDY Transplantation. 67: S239. DOI: 10.1097/00007890-199904150-00955 |
0.392 |
|
| 1999 |
Kung L, Noujaim J, Halloran PF. CYCLOSPORINE AND TACROLIMUS COMPLETELY INHIBIT IMMUNE ACTIVATION DESPITE INCOMPLETE INHIBITION OF CALCINEURIN (CN) ACTIVITY: EVIDENCE FOR A SPECIALIZED CN COMPARTMENT Transplantation. 67: S213. DOI: 10.1097/00007890-199904150-00852 |
0.619 |
|
| 1999 |
Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. Interleukin-2-Receptor Blockade With Daclizumab to Prevent Acute Rejection in Renal Transplantation Journal of Urology. 161: 1034-1035. DOI: 10.1016/S0022-5347(01)61859-7 |
0.382 |
|
| 1998 |
Halloran P. Funding for transplant research. Transplant Immunology. 6: 269. PMID 10342742 DOI: 10.1016/S0966-3274(98)80018-X |
0.327 |
|
| 1998 |
Halloran PF, Kung L, Noujaim J. Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplantation Proceedings. 30: 2167-70. PMID 9723430 DOI: 10.1016/S0041-1345(98)00577-6 |
0.615 |
|
| 1998 |
Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. The New England Journal of Medicine. 338: 161-5. PMID 9428817 DOI: 10.1056/Nejm199801153380304 |
0.399 |
|
| 1998 |
Ivanyi B, Fahmy H, Szenohradszky P, Hansen H, Olsen S, Halloran P, Solez K. MULTILAMELLATION OF THE PERITUBULAR CAPILLARY BASEMENT MEMBRANE IN CHRONIC RENAL ALLOGRAFT REJECTION Transplantation. 66: S43. DOI: 10.1097/00007890-199810270-00201 |
0.304 |
|
| 1998 |
Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, et al. RANDOMIZED COMPARATIVE TRIAL OF PROGRAF (TACROLIMUS) IN COMBINATION WITH AZATHIOPRINE OR MYCOPHENOLATE MOFETIL VS. NEORAL (CYCLOSPORINE) WITH MYCOPHENOLATE MOFETIL AFTER KIDNEY TRANSPLANTATION Transplantation. 65: 244. DOI: 10.1097/00007890-199805131-00659 |
0.375 |
|
| 1998 |
Takei Y, Sims TN, Halloran PF. DIFFERENTIAL USAGE OF THE CLASS II TRANSACTIVATOR (CIITA) PROMOTERSIN VIVO Transplantation. 65: 106. DOI: 10.1097/00007890-199805131-00111 |
0.664 |
|
| 1998 |
Kung L, Halloran PF. MECHANISM OF ACTION OF CYCLOSPORINE A (CsA) AND TACROLIMUS (FK) ON CALCINEURIN (CN) Transplantation. 65: 104. DOI: 10.1097/00007890-199805131-00103 |
0.617 |
|
| 1997 |
Sims TN, Goes NB, Ramassar V, Urmson J, Halloran PF. In vivo class II transactivator expression in mice is induced by a non-interferon-gamma mechanism in response to local injury. Transplantation. 64: 1657-64. PMID 9422398 DOI: 10.1097/00007890-199712270-00005 |
0.691 |
|
| 1997 |
Batiuk TD, Kung L, Halloran PF. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. The Journal of Clinical Investigation. 100: 1894-901. PMID 9312192 DOI: 10.1172/Jci119719 |
0.634 |
|
| 1997 |
Halloran PF, Goes N, Urmson J, Ramassar V, Hobart M, Sims T, Lui SL, Miller LW. MHC expression in organ transplants: lessons from the knock-out mice. Transplantation Proceedings. 29: 1041-4. PMID 9123189 DOI: 10.1016/S0041-1345(96)00361-2 |
0.685 |
|
| 1997 |
Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation. 63: 39-47. PMID 9000658 DOI: 10.1097/00007890-199701150-00008 |
0.403 |
|
| 1997 |
Sims TN, Elliott JF, Ramassar V, Denney DW, Halloran PF. Mouse class II transactivator: cDNA sequence and amino acid comparison with the human class II transactivator. Immunogenetics. 45: 220-2. PMID 8995190 DOI: 10.1007/S002510050193 |
0.655 |
|
| 1997 |
Hobart M, Ramassar V, Goes N, Urmson J, Halloran PF. The induction of class I and II major histocompatibility complex by allogeneic stimulation is dependent on the transcription factor interferon regulatory factor 1 (IRF-1): observations in IRF-1 knockout mice. Transplantation. 62: 1895-901. PMID 8990383 DOI: 10.1097/00007890-199612270-00037 |
0.301 |
|
| 1996 |
Keown P, Häyry P, Morris P, Stiller C, Barker C, Carr L, Landsberg D, Hardie I, Rigby R, Isoniemi H, Gray D, Belitsky P, McDonald A, Mathew T, Clarkson A, ... ... Halloran P, et al. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation Transplantation. 61: 1029-1037. DOI: 10.1097/00007890-199604150-00008 |
0.364 |
|
| 1995 |
Oellerich M, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, Lindholm A, Halloran P, Gallicano K, Wonigeit K. Lake Louise Consensus Conference on cyclosporin monitoring in organ transplantation: report of the consensus panel. Therapeutic Drug Monitoring. 17: 642-54. PMID 8588235 DOI: 10.1097/00007691-199512000-00017 |
0.343 |
|
| 1990 |
Halloran PF, Wadgymar A, Ritchie S, Falk J, Solez K, Srinivasa NS. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation. 49: 85-91. PMID 2301035 DOI: 10.1097/00007890-199001000-00019 |
0.301 |
|
| 1990 |
Shoskes DA, Parfrey NA, Halloran PF. Increased major histocompatibility complex antigen expression in unilateral ischemic acute tubular necrosis in the mouse. Transplantation. 49: 201-7. PMID 2105546 DOI: 10.1097/00007890-199001000-00045 |
0.309 |
|
| 1988 |
Halloran P, Aprile M, Farewell V. Factors influencing early renal function in cadaver kidney transplants. A case-control study. Transplantation. 45: 122-127. PMID 3276040 DOI: 10.1097/00007890-198801000-00027 |
0.386 |
|
| Show low-probability matches. |